WASHINGTON (Reuters) - An initial review of MannKind Corp's experimental inhaled insulin device, Afrezza, by U.S. Food and Drug Administration staff raised multiple questions about its safety and effectiveness in treating diabetes. The reviewers issued their report before a meeting on April 1 of outside advisers to the FDA who will discuss clinical trial data and advise on whether the product should be approved. Afrezza is a whistle-sized inhaler designed to deliver more effective, rapid-acting insulin than injectable products offered by Eli Lilly and Co. and Denmark's Novo Nordisk. ...
via Health News Headlines - Yahoo News
Read More Here.. 
Lake forest health and fitness http://ift.tt/QnelGv
No comments:
Post a Comment